Tilray

TLRY

Market cap $1.89B

As a whole, the U.S. stock market wanted to partake of Tilray Brands (TLRY 5.00%) on Wednesday. The Canadian cannabis company's shares enjoyed a 5% lift on the day, although this was due to external news rather than any proprietary development.

Tilray Brands Inc (NASDAQ:TLRY) shares are trading higher on Wednesday after a Marijuana Moment report cited findings from a new study showing medical cannabis legalization leads to significant reductions in opioid prescriptions. Here's what investors need to know.

Tilray Brands (TLRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tilray's return to profitability, stronger cash flow, and expanding global cannabis and beverage operations highlight its renewed growth story.

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, has announced plans to expand its medical cannabis operations into Panama. In connection with its expansion into Panama, Tilray has entered into a joint venture with Top Tech Global Inc. (“Top Tech”), whose members have extensive experience in the distribution of medical devices since 2014.  Together, Tilray and Top Tech, through their joint venture company, Solana Life Group, have received a medical cannabis license issued by the National Directorate of Pharmacy and Drugs in Panama authorizing the cultivation, manufacturing, import, export, distribution and sale of medical cannabis in Panama.

Tilray stock price surged to the highest point since April last year and then pulled back after its mixed financial results. TLRY's US shares ended the week at $1.72, down by 26% from its highest point this year.

The Canadian cannabis sector continues to attract investors as North American legalization momentum gains strength. Recently, U.S. regulators advanced discussions on cannabis rescheduling, signaling a potential shift toward federal reform. This news lifted optimism across the industry, especially for Canadian producers eyeing future U.S. market entry. Currently, the U.S. cannabis market generates over $35 billion in annual sales and is projected to surpass $57 billion by 2030. Canadian companies are strategically positioning themselves to benefit from this growth through cross-border partnerships and product innovation. Moreover, many are expanding into wellness, beverages, and medical research to diversify revenue streams. As legalization efforts accelerate, Canadian cannabis firms could see renewed investor interest and significant upside potential in 2025.

Tilray Brands (TLRY -15.95%), the Canadian marijuana stock, closed 22% higher yesterday after reporting a surprise profit for fiscal Q1. That's the good news.

This week marked the start of earnings season with several major companies reporting results, including Delta Air Lines and PepsiCo, while the big banks like JPMorgan Chase, Citigroup, and Wells Fargo are set to report next week. Investors are closely watching these early reports for cues on the broader economic landscape amid ongoing uncertainties.

Tilray reported strong Q1-2026 results with net income and revenue growth, sparking a sector-wide rally in cannabis stocks. Tilray's performance was driven by international and Canadian cannabis sales. I continue a Hold rating due to uncertainty around cannabis rescheduling and recent price surges.